| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Sozinibercept | OPT-302; VGX-300 | Phase 3 Clinical | Orphan Europe Sarl | Neovascularization, Pathologic; Retinal Diseases; Diabetic macular oedema; Retinal Degeneration; Eye Diseases; Macular Degeneration | Details |
| EG-016 | EG-016; Ad-VEGF-A | Phase 2 Clinical | Ark Therapeutics Ltd | Peripheral Vascular Diseases | Details |
| EG-011 | EG-011; Ad-VEGF-D | Phase 2 Clinical | Ark Therapeutics Ltd | Angina Pectoris | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



